Japanese Cannabis Users Rarely Progressed to Other Drugs, Challenging the Gateway Hypothesis

Among 3,900 Japanese cannabis users surveyed, cannabis was typically the third substance tried (after alcohol and tobacco), and nearly half who reported it as their third drug did not use any other substances afterward.

Masataka, Yuji et al.·Neuropsychopharmacology reports·2025·Moderate EvidenceCross-Sectional
RTHC-07073Cross SectionalModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Cross-Sectional
Evidence
Moderate Evidence
Sample
N=3,900

What This Study Found

Tobacco and alcohol were the most common initial substances, with cannabis typically third. The odds of progressing from cannabis to other substances were low: alcohol 1.25, tobacco 0.77, methamphetamine 0.08, other illicit drugs 0.78. Nearly half of those who reported cannabis as their third drug did not use other substances afterward.

Key Numbers

N = 3,900. 81.5% male. Largest age group: 20-24. Cannabis typically 3rd substance after alcohol and tobacco. Odds of post-cannabis use: methamphetamine 0.08, other illicit 0.78, tobacco 0.77, alcohol 1.25. ~50% used no other drugs after cannabis.

How They Did This

Anonymous online survey of 3,900 individuals reporting lifetime cannabis use in Japan, recruited via social media in January 2021. Substance use progression was visualized using a Sankey diagram. Odds ratios calculated for likelihood of using other substances following cannabis use.

Why This Research Matters

Japan maintains some of the strictest cannabis laws globally, making this a unique context for testing the gateway hypothesis. Even in a prohibitionist setting, cannabis rarely led to harder drug use, suggesting the "gateway" pattern is not an inherent property of cannabis itself.

The Bigger Picture

The gateway drug hypothesis has been a cornerstone of drug prohibition policy worldwide. This study from Japan, where cannabis use carries severe legal penalties, finds little support for the theory even in a context where cannabis users might be more risk-tolerant than in lenient jurisdictions.

What This Study Doesn't Tell Us

Online convenience sample may over-represent younger, tech-savvy users. Self-reported data may be affected by recall bias. Japan's strict drug enforcement may suppress progression to other drugs through deterrence rather than disproving gateway mechanisms. Social media recruitment introduces selection bias.

Questions This Raises

  • ?Would results differ in countries with legal cannabis access?
  • ?Does Japan's strict enforcement suppress drug progression that might otherwise occur?

Trust & Context

Key Stat:
0.08 odds of progressing from cannabis to methamphetamine
Evidence Grade:
Large survey with quantified progression odds, but online convenience sample and self-report introduce bias. Moderate evidence for the Japanese context.
Study Age:
Published in 2025 with 2021 survey data.
Original Title:
Revisiting the Gateway Drug Hypothesis for Cannabis: A Secondary Analysis of a Nationwide Survey Among Community Users in Japan.
Published In:
Neuropsychopharmacology reports, 45(3), e70033 (2025)
Database ID:
RTHC-07073

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

A snapshot of a population at one point in time.

What do these levels mean? →

Frequently Asked Questions

Is cannabis a gateway drug?

This study found little support for the theory in Japan. Cannabis users had very low odds of progressing to harder drugs, and nearly half used no other substances after cannabis.

Why study this in Japan specifically?

Japan has extremely strict cannabis laws, so if the gateway effect were real, it might be most visible in a context where cannabis users are already demonstrating willingness to break drug laws. The lack of progression even here weakens the gateway argument.

Read More on RethinkTHC

Cite This Study

RTHC-07073·https://rethinkthc.com/research/RTHC-07073

APA

Masataka, Yuji; Katayama, Munenori; Umemura, Futaba; Sugiyama, Takeshi; Miki, Naoko; Akahoshi, Yoshiyuki; Oka, Chihiro; Asahi, Takashi; Matsumori, Takashi; Takumi, Ichiro; Murata, Hidetoshi; Matsumoto, Toshihiko. (2025). Revisiting the Gateway Drug Hypothesis for Cannabis: A Secondary Analysis of a Nationwide Survey Among Community Users in Japan.. Neuropsychopharmacology reports, 45(3), e70033. https://doi.org/10.1002/npr2.70033

MLA

Masataka, Yuji, et al. "Revisiting the Gateway Drug Hypothesis for Cannabis: A Secondary Analysis of a Nationwide Survey Among Community Users in Japan.." Neuropsychopharmacology reports, 2025. https://doi.org/10.1002/npr2.70033

RethinkTHC

RethinkTHC Research Database. "Revisiting the Gateway Drug Hypothesis for Cannabis: A Secon..." RTHC-07073. Retrieved from https://rethinkthc.com/research/masataka-2025-revisiting-the-gateway-drug

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.